Table 1.
The REGARD Trial: Ramucirumab versus Placebo in Gastric Cancer
| Efficacy measure | Ramucirumab + best supportive therapy (N = 238) |
Placebo + best supportive therapy (N = 117) |
|---|---|---|
| Overall survival | ||
| Deaths, N (%) | 179 (75) | 99 (85) |
| Median, mo | 5.2 (95% CI, 4.4–5.7) | 3.8 (95% CI, 2.8–4.7) |
| Hazard ratio | 0.78 (95% CI, 0.60–0.998) | |
| Stratified log-rank P value | .047 | |
| Progression-free survival | ||
| Events, N (%) | 199 (84) | 108 (92) |
| Median, mo | 2.1 (95% CI, 1.5–2.7) | 1.3 (95% CI, 1.3–1.4) |
| Hazard ratio | 0.48 (95% CI, 0.38–0.62) | |
| Stratified log-rank P value | <.001 | |
CI indicates confidence interval.
Source: Cyramza (ramucirumab) injection prescribing information; December 2014.